Issue 3/2014
Content (29 Articles)
The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis
Ezzeldin M. Ibrahim, Meteb E. Al-Foheidi, Mubarak M. Al-Mansour, Ghieth A. Kazkaz
Metabolic isoenzyme shifts in cancer as potential novel therapeutic targets
S. N. Ononye, W. Shi, V. B. Wali, B. Aktas, T. Jiang, C. Hatzis, L. Pusztai
A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer
Sepideh Gholami, Andrew Marano, Nanhai G. Chen, Richard J. Aguilar, Alexa Frentzen, Chun-Hao Chen, Emil Lou, Sho Fujisawa, Clarisse Eveno, Laurence Belin, Pat Zanzonico, Aladar Szalay, Yuman Fong
Natural history of tumor growth and immune modulation in common spontaneous murine mammary tumor models
Ekram Gad, Lauren Rastetter, Meredith Slota, Marlese Koehnlein, Piper M. Treuting, Yushe Dang, Sasha Stanton, Mary L. Disis
Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study
D. Balmativola, C. Marchiò, M. Maule, L. Chiusa, L. Annaratone, F. Maletta, F. Montemurro, J. Kulka, P. Figueiredo, Z. Varga, I. Liepniece-Karele, G. Cserni, E. Arkoumani, I. Amendoeira, G. Callagy, A. Reiner-Concin, A. Cordoba, S. Bianchi, T. Decker, D. Gläser, C. Focke, P. van Diest, D. Grabau, E. Lips, J. Wesseling, R. Arisio, E. Medico, C. Wells, A. Sapino
Tumor-infiltrating CD8+ and FOXP3+ lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy
Minoru Miyashita, Hironobu Sasano, Kentaro Tamaki, Monica Chan, Hisashi Hirakawa, Akihiko Suzuki, Hiroshi Tada, Go Watanabe, Noriko Nemoto, Saki Nakagawa, Takanori Ishida, Noriaki Ohuchi
Amrubicin as second- or third-line treatment for women with metastatic HER2-negative breast cancer: a Sarah Cannon Research Institute phase 1/2 trial
Denise A. Yardley, Eric Raefsky, John D. Hainsworth, Howard A. Burris III, Victor Priego, Alejandro Inclan
Association between rim enhancement of breast cancer on dynamic contrast-enhanced MRI and patient outcome: impact of subtype
Alexander M. Th. Schmitz, Claudette E. Loo, Jelle Wesseling, Ruud M. Pijnappel, Kenneth G. A. Gilhuijs
Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies
Chris Twelves, Javier Cortes, Linda Vahdat, Martin Olivo, Yi He, Peter A. Kaufman, Ahmad Awada
Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy
Joanne Mortimer, Jae Jung, Yuan Yuan, Laura Kruper, Daphne Stewart, Samuel Chung, Kim Wai Yu, Mary Mendelsohn, Massimo D’Apuzzo, Bernard Tegtmeier, Sanjeet Dadwal
Pharmacogenomic diversity of tamoxifen metabolites and estrogen receptor genes in Hispanics and non-Hispanic whites with breast cancer
Leticia B. A. Rangel, Jodi L. Taraba, Christopher R. Frei, Lon Smith, Gladys Rodriguez, John G. Kuhn
NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer
C. Palmieri, S. Cleator, L. S. Kilburn, S. B. Kim, S.-H. Ahn, M. Beresford, G. Gong, J. Mansi, E. Mallon, S. Reed, K. Mousa, L. Fallowfield, M. Cheang, J. Morden, K. Page, D. S. Guttery, B. Rghebi, L. Primrose, J. A. Shaw, A. M. Thompson, J. M. Bliss, R. C. Coombes
Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG)
Emmanouil Saloustros, Nikolaos Malamos, Ioannis Boukovinas, Stylianos Kakolyris, Charalampos Kouroussis, Athanasios Athanasiadis, Nikolaos Ziras, Nikolaos Kentepozidis, Parisis Makrantonakis, Aristidis Polyzos, Charalampos Christophyllakis, Vassilios Georgoulias, Dimitrios Mavroudis
Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled analysis
C. A. Drukker, S. G. Elias, M. V. Nijenhuis, J. Wesseling, H. Bartelink, P. Elkhuizen, B. Fowble, P. W. Whitworth, R. R. Patel, F. A. de Snoo, L. J. van ’t Veer, P. D. Beitsch, E. J. Th. Rutgers
Methylation of the BRCA1 promoter in peripheral blood DNA is associated with triple-negative and medullary breast cancer
Satish Gupta, Katarzyna Jaworska-Bieniek, Steven A. Narod, Jan Lubinski, Tomasz K. Wojdacz, Jakubowska Anna
Association of SULT1A1 Arg213His polymorphism with male breast cancer risk: results from a multicenter study in Italy
L. Ottini, P. Rizzolo, I. Zanna, V. Silvestri, C. Saieva, M. Falchetti, G. Masala, A. S. Navazio, C. Capalbo, S. Bianchi, S. Manoukian, M. Barile, P. Peterlongo, M. A. Caligo, L. Varesco, S. Tommasi, A. Russo, G. Giannini, L. Cortesi, G. Cini, M. Montagna, P. Radice, D. Palli
Novel and recurrent BRCA2 mutations in Italian breast/ovarian cancer families widen the ovarian cancer cluster region boundaries to exons 13 and 14
Anna Coppa, Amelia Buffone, Carlo Capalbo, Arianna Nicolussi, Sonia D’Inzeo, Francesca Belardinilli, Valeria Colicchia, Marialaura Petroni, Teresa Granato, Cecilia Midulla, Massimo Zani, Sergio Ferraro, Isabella Screpanti, Alberto Gulino, Giuseppe Giannini
Impact of histological subtype on long-term outcomes of neuroendocrine carcinoma of the breast
Jordan M. Cloyd, Rachel L. Yang, Kimberly H. Allison, Jeffrey A. Norton, Tina Hernandez-Boussard, Irene L. Wapnir
Association between persistence with mammography screening and stage at diagnosis among elderly women diagnosed with breast cancer
Ami Vyas, Suresh Madhavan, Usha Sambamoorthi
Degree of urbanization and mammographic density in Dutch breast cancer screening participants: results from the EPIC-NL cohort
Marleen J. Emaus, Marije F. Bakker, Rob M. J. Beelen, Wouter B. Veldhuis, Petra H. M. Peeters, Carla H. van Gils
Epigenome-wide methylation in DNA from peripheral blood as a marker of risk for breast cancer
Gianluca Severi, Melissa C. Southey, Dallas R. English, Chol-hee Jung, Andrew Lonie, Catriona McLean, Helen Tsimiklis, John L. Hopper, Graham G. Giles, Laura Baglietto
Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers
Werner Pfeifer, Anna P. Sokolenko, Olga N. Potapova, Alexandr A. Bessonov, Alexandr O. Ivantsov, Sergey A. Laptiev, Olga A. Zaitseva, Olga S. Yatsuk, Dmitry E. Matsko, Tatiana Yu. Semiglazova, Alexandr V. Togo, Evgeny N. Imyanitov
Concerns about methods for determination of estrogens in body fluids
Robert T. Chatterton, Miguel Muzzio, Peter H. Gann
MRI screening of women with hereditary predisposition to breast cancer: diagnostic performance and survival analysis
Kukatharmini Tharmaratnam, Anne Irene Hagen, Pål Møller
The frequency of the BLM p.Q548X (c.1642C>T) mutation in breast cancer patients from Russia is no higher than in the general population
Maksim S. Anisimenko, Anton E. Kozyakov, Galina A. Paul, Sergey P. Kovalenko
Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers
Jennifer T. Loud
The frequency of the BLM*p.Q548X (c.1642C > T) mutation in breast cancer patients from Russia
Evgeny Imyanitov, Darya Prokofyeva, Natalia Bogdanova, Thilo Dörk
Erratum to: Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours
Brigid C. Browne, Alex J. Eustace, Susan Kennedy, Neil A. O’Brien, Kasper Pedersen, Martina S. J. McDermott, Annemarie Larkin, Jo Ballot, Thamir Mahgoub, Francesco Sclafani, Stephen Madden, John Kennedy, Michael J. Duffy, John Crown, Norma O’Donovan